Cytokinetics’ Myqorzo Launch Gains Traction, but the Hard Test Is Ahead

A new commercial drug is beginning to show up in Cytokinetics’ accounts. Myqorzo generated $25.3 million in net product revenue in the second quarter of 2026, up from $4.8 million in its initial, partial quarter. The U.S. contributed $23 million; the other $2.3 million came from German distributors’ initial inventory purchases, not necessarily prescriptions to patients. That distinction matters as investors judge how much of the launch can translate into sustained demand.

The early uptake measures are encouraging. By June 30, more than 700 healthcare providers had prescribed the drug and about 1,500 patients had received it, Cytokinetics said; over 80% of patients on therapy were on paid prescriptions. Myqorzo, or aficamten, is a once-daily cardiac myosin inhibitor approved by the FDA for adults with symptomatic obstructive hypertrophic cardiomyopathy, a condition in which thickened heart muscle can obstruct blood flow. Its U.S. approval came in December 2025, and the company brought it to market in January.

The growth opportunity extends beyond the first indication, but it is not yet in hand. Cytokinetics plans to submit an FDA application in the fourth quarter seeking approval for non-obstructive HCM, after its Phase 3 ACACIA-HCM trial met both primary endpoints. The company has said a launch in that population could follow in 2027 if regulators approve it. Overseas expansion is also underway: Germany launched in June, while the company expects to enter more than five additional markets by the first half of 2027.

The commercial ramp is costly. Cytokinetics reported a $198.8 million second-quarter net loss, and raised its 2026 research-and-selling expense outlook to $860 million to $890 million, citing commercial preparation and plans for the potential HCM expansion. Its $1.7 billion cash and investments balance at quarter-end offers room to fund that push, though a stock offering supplied about $760 million of it. The company’s sales rose, but the business is far from self-funding.

For CYTK, the next proof point is whether prescriptions and paid treatment keep climbing after the initial launch wave, while regulatory and access decisions open more markets. Myqorzo has moved Cytokinetics from a development-stage story toward a commercial one. Turning that transition into a durable growth engine will take more than a promising first two quarters.